Frequently Asked Questions
The market is segmented based on , By Type (Monoclonal Antibodies, Small-Molecules, Immunotoxins, Others), Therapy Area (Oncology, Cardiometabolism, Immunology, Infectious Diseases, Neuroscience, Ophthalmology, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
.
The Global Injectable Targeted Therapy Market size was valued at USD 610.67 USD Billion in 2021.
The Global Injectable Targeted Therapy Market is projected to grow at a CAGR of 12% during the forecast period of 2022 to 2029.
The major players operating in the market include F. Hoffmann La Roche , Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Pfizer , GSK plc, Novartis AG, Bayer AG, Lilly, Merck & Co. , Sun Pharmaceutical Industries , Aurobindo Pharma, Lupin, Endo Pharmaceuticals plc, Zydus Group, Bausch Health Companies .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
